Linyi

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lupus (SLE)3 trials
• Sjögren's disease2 trials
• Ankylosing spondylitis1 trial
• Familial hypercholesterolaemia1 trial

Phase

• Phase 37 trials

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Recruiting

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

  NCT05888103· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05350072· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

  NCT04732117· Phase 3· Novartis Pharmaceuticals· Source